FDA Approved Expanded Indication for Max 3™ Syringeless MR Injector from Bracco
On November 25, 2025, Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., announced that the U.S. Food and Drug Administration (FDA) expanded the indication for its Max 3™ Rapid Exchange and Syringeless Injector for use in MRI procedures. The system, which had already been cleared for single-dose and multi-dose vials, was now also authorized for use with the newly approved VUEWAY® (gadopiclenol) Injection Imaging Bulk Package (IBP) in 30 mL and 50 mL formats.
The Max 3™ injector, recognized as the first and only syringeless MRI injector in the U.S. market, had been...